Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness

Table 2 Counts of potentially novel drug-drug interaction claims

Drug	Number of VA-NDFRT DDIs		Number of VA-NDFRT DDIs that were potentially novel
	found for the drug		to at least one product label. N (%)
	Significant	Critical	Significant	Critical
Amitriptyline	16	8	8(50)	3 (38)
Amoxapine	15	8	11 (73)	4 (50)
Bupropion	7	4	5 (71)	3 (75)
Citalopram	25	9	5 (20)	4 (44)
Desipramine	16	10	16 (100)	6 (60)
Doxepin	15	9	15 (100)	9 (100)
Duloxetine	26	8	12 (46)	3 (38)
Escitalopram	13	3	3 (23)	1 (33)
Fluoxetine	51	14	28 (55)	8 (57)
Imipramine	18	10	18 (100)	6 (60)
Mirtazapine	2	5	1 (50)	1 (20)
Nefazodone	39	20	31 (80)	11 (55)
Nortriptyline	16	11	16 (100)	11 (100)
Paroxetine	33	11	15 (46)	5 (45
Selegiline	2	47	1 (50)	23 (49)
Sertraline	28	8	7 (25)	3 (38)
Tranylcypromine	3	61	1 (33)	33 (54)
Trazodone	8	10	8 (100)	10 (100)
Trimipramine	17	10	17 (100)	10 (100)
Venlafaxine	21	6	21 (100)	6 (100)

The number and proportion of VA NDF-RT drug-drug interactions that were noted as potentially novel to the Drug Interaction section of at least one antidepressant product label. For these drugs, a potentially novel interaction was an NDF-RT interaction that was 1) not mentioned in the Drug Interaction section of a drug’s product label based on a case-insensitive string match, and 2) not listed as an interacting drug based on our review (prior to the study) of a single manually-reviewed product label the listed drug.

ISSN: 2041-1480